Background. As the U.S. population ages, the number of total hip and knee arthroplasties (THA, TKA respectively) is expected to increase. Surgical site infections (SSIs) following these procedures contribute substantial morbidity, mortality and costs.
Background. Kidney and pancreas transplantation is a preferred treatment modality to ameliorate the renal failure and other comorbidities associated with type I diabetes. Postoperative surgical site infections (SSIs) and urinary tract infections have been noted to be the most common infections seen after SKP transplantation. This study assessed the incidence of SSIs and risk factors for these SSIs in SKP transplant recipients within the first three months after transplantation.
Methods. This retrospective, single-center, cohort study was conducted at the Toronto General Hospital of the University Health Network, Toronto, Canada from January 2000 to December 2015. SSIs were classified according to the Centers for Disease Control classification as superficial, deep and organ/space.
Results. Four hundred and forty-five adult patients were enrolled. The median age of the recipients was 51 (range 19 to 71) years old, and 64.9% were males. SSIs were documented in 108 (24.3%) patients. Organ/space SSIs predominated, accounting for 59 (54.6%) patients followed by superficial SSI (n = 47, 43.5%) with only deep infections. Factors predictive of SSIs by multivariate analysis were pancreas cold ischemic time (Odds ratio 1.002, P = 0.11) and simultaneous SKP transplant (as compared with pancreas transplant alone, Odds ratio 2.38, P = 0.003). SSIs were associated with longer duration of hospital stay (P < 0.001).
Conclusion. Organ/space SSIs remain a serious and common complication after SKP transplant. Longer pancreas cold ischemic time and simultaneous kidney and pancreas transplantation were the risk factors predictive of SSI. Efforts to improve pancreatic cold ischemic time and optimize perioperative antimicrobial prophylaxis in high-risk patients targeting potential pathogens producing SSIs in SKP transplant patients are warranted.
Disclosures. All authors: No reported disclosures. Methods. To evaluate the effectiveness of fosfomycin tromethamine prophylaxis in preventing post-TRUSPB infectious complications, we conducted a case-control study nested in a cohort of patients undergoing TRUSPB between 2002 and 2016 in a secondary and tertiary care hospital in Canada. It included patients who developed post-TRUSPB bacteremia and/or urinary sepsis. Controls were randomly selected from among TRUSPB patients without such complications. Four prophylaxis periods were defined across the study: i) ciprofloxacin, low-resistance period (CIPRO-LOW), [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] ; ii) ciprofloxacin, high-resistance period (CIPRO-HIGH), 2010-October 2013; iii) oral fosfomycin tromethamine, one dose (FOSFO1), December 2013-September 2015; and iv) oral fosfomycin tromethamine, two doses (FOSFO2), October 2015-June 2016. Incidence rates of infection were calculated from the cohort. Crude and adjusted odds ratios and their 95% confidence intervals were calculated using logistic regression, using the nested case-control study.
Effectiveness of Fosfomycin Tromethamine Prophylaxis in Preventing
Results. During the study, 9527 TRUSPBs were performed, resulting in 138 cases of urinary sepsis (58% with bacteremia). The incidence rates were 1.82% with CIPRO-HIGH, 3.54% with the FOSFO1 regimen (P = 0.004, compared with CIPRO-HIGH), and 2.73% with the FOSFO2 regimen (P = 0.19, compared with CIPRO-HIGH).Patients receiving FOSFO1 (risk ratio: 2.18; P = 0.0001) and FOSFO2 (risk ratio: 1.84; P = 0.05) had a higher risk of hospitalization for a post-TRUSPB infectious complication than patients receiving CIPRO-HIGH did. Although Escherichia coli remained the predominant pathogen with fosfomycin-based regimens, the proportion of infections with Klebsiella spp. was significantly higher (20/66; 30.3%) than that with ciprofloxacin-based regimens (2/77; 2.5%; P < 0.0001). Independent risk factors for infection were the prophylactic regimen administered, the presence of urological comorbidity, and diabetes.
Conclusion. Fosfomycin tromethamine was not an effective alternative to ciprofloxacin for preventing post-TRUSPB urinary sepsis, highlighting the need for novel antibacterial prophylaxis approaches. Background. Hepatitis B (HBV) co-infection increases the risk for liver-related morbidity among HIV-infected patients. Department of Health and Human Services (DHHS) guidelines for the management of HIV/HBV co-infection recommend six-monthly monitoring of blood tests. We assessed longitudinal adherence to these guidelines among patients enrolled in the DC Cohort Study, a city-wide clinical cohort in Washington, DC.
Methods. Patients ≥18 years old who were enrolled between January 1, 2011 and March 31, 2016 and had ≥6 months of follow-up were included. Advanced liver fibrosis was defined as having a FIB-4 score >3.25 calculated from same-day platelet, AST and ALT results. Viral suppression (VS) was defined as having undetectable HIV VL (<200 copies/mL). Chronic HBV status was determined using ICD 9 and 10 diagnosis codes. Clinical targets were defined as the proportion tested for HBV viral load (VL), platelet count and AST (markers of HBV care) along with HIV VL and CD4 count tests (markers of HIV care) every six months following enrollment.
Results. Among 7,631 HIV-infected patients, 354 (4.6%) had chronic HBV among whom 22 (6.2%) had advanced fibrosis. Compared with HIV-mono-infected patients, HIV/HBV patients were more likely to be male (86% vs 72%, P < 0.001) and had a history of AIDS (49% vs 37%, P < 0.001). Although HIV VS was high in both groups, co-infected patients were less likely to have undetectable HIV VL (88% in HIV only vs 84% in HIV/HBV, P = 0.026). HIV/HBV patients were nearly four times less likely to be tested for HBV than for HIV VL in the first six months (21% vs 79%, P <0.0001) and eight times less likely in the last six months of observation (6% vs 49%, P <0.0001). Comparing the first six months to the last six months of observation, the proportion of patients tested for AST (77% and 50% P < 0.0001) and platelets (76% and 57% P < 0.0001) declined.
Conclusion. Adherence to the DHHS management guidelines for monitoring HBV VL among HIV/HBV co-infected patients was low. AST and platelet counts were monitored at a similar frequency to HIV VL, suggesting that these markers may have been checked as part of routine HIV care than for HBV monitoring. Focusing on adherence to guidelines may ensure early detection of complications and provide patients with timely and appropriate care. Saturday, October 7, 2017: 12:30 PM Background. Co-infection with HIV and hepatitis B virus (HBV) is common, reaching 23% in Uganda, and can accelerate HBV disease progression. Inflammation contributes to the pathogenesis of both viruses. We compared serological biomarkers of inflammation and FIB-4 scores (to predict liver fibrosis) stratified by HIV and HBV status in a Ugandan cohort.
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Markers of Cirrhosis and Inflammation in HIV/HBV Co-infection in a Ugandan
Methods. Subjects with HIV/HBV co-infection were matched up to 2:1 by age and gender with HIV-monoinfected, HBV-monoinfected, and uninfected controls from the Ugandan site of the African Cohort Study (AFRICOS). Demographic and laboratory characteristics, including inflammatory biomarkers, were compared between the groups. FIB-4 scores were stratified as <1.45, 1.45-3.25, and >3.25 for those unlikely to have advanced fibrosis, indeterminate, and likely to have advanced fibrosis, respectively (resp.), in the HIV/HBV and HIV groups, which had these data available.
Results. Within the Ugandan subset of AFRICOS, 31 HIV/HBV co-infected patients were available and compared with 62 HIV-monoinfected, 7 (all that were available) HBV-monoinfected, and 62 uninfected subjects. Median age was 37 (range 19-67) years and 78% were male. The HBV group, as compared with the HIV/HBV, HIV, and uninfected groups, had higher prevalence of hepatitis C antibody (29%, 6%, 2%, 3%, resp.; P = 0.04), fewer other active infections (0%, 48%, 52%, 26%, resp.; P = 0.002), fewer non-antiretroviral medications (median 0, 1, 2, 0, resp.; P < 0.001), and a smaller proportion on an antimicrobial (0%, 32%, 37%, 18%, resp.; P = 0.03). The HIV/HBV group had generally higher levels of inflammation overall and statistically had significantly higher levels of MMP-12 and lower levels of FGF-23 compared with the other groups (Figure 1) . The HIV/HBV group had a lower proportion of subjects unlikely to have advanced fibrosis by FIB-4 (Figure 2 ; P = 0.046).
Conclusion. Elevated MMP-12 in the HIV/HBV group suggests that elastin degradation may be a mechanism contributing to the accelerated progression of liver disease seen in co-infection. Prior literature demonstrated that FGF-23 is elevated in end-stage liver disease and predicts mortality, but we did not observe higher levels in HIV/HBV co-infection in this cohort with little advanced liver disease. Further studies are needed to characterize the inflammatory milieu and evaluate the impact of time and treatment of HIV/HBV.
